New Style Guide,GLP Direct Peptide Reactivity Assay (DPRA

The DPRA peptide is a critical component in modern toxicology, specifically within the realm of skin sensitization testing. This in chemico method, scientifically known as the Direct Peptide Reactivity Assay (DPRA), plays a pivotal role in evaluating the potential of chemicals to cause allergic contact dermatitis. As a recognized OECD test guideline method, the DPRA is instrumental in predicting a chemical's capacity to act as a skin sensitizer, offering a significant advancement in characterization of sensitizing elements and moving away from animal testing.

At its core, the DPRA models the first key event in the skin sensitization Adverse Outcome Pathway (AOP). This molecular initiating event involves the covalent binding of electrophilic chemicals to nucleophilic amino acid residues in skin proteins. The DPRA specifically focuses on the reactivity of chemicals with cysteine- or lysine-containing peptide sequences. These synthetic peptides are custom material containing phenylalanine to facilitate UV detection, with either cysteine or lysine serving as the reactive center. By quantifying the remaining concentration of cysteine- or lysine-containing peptide after incubation with a test chemical, the assay determines the extent of peptide depletion, which is directly indicative of the chemical's reactivity.

The DPRA is considered one of three test methods alongside KeratinoSens™ and h-CLAT for the comprehensive assessment of skin sensitization potential. Its robustness lies in its ability to provide a direct measure of protein reactivity. This involves instrumental analysis of the reactivity of chemicals with proteins, specifically by measuring the kinetic rates of cysteine peptide depletion using the kinetic DPRA assay or by quantifying peptide depletion after a defined incubation period, typically 24 hours. The DPRA (direct peptide reactivity assay), as per OECD 442C, is a validated approach for assessing protein reactivity of chemical compounds.

Several variations and advancements of the DPRA have been developed to enhance its utility. The Spectrophotometric Direct Peptide Reactivity Assay (Spectro-DPRA), for instance, is a high-throughput in chemico assay designed to evaluate Key Event 1 (KE1)—covalent binding. Furthermore, the Kinetic Direct Peptide Reactivity Assay (kDPRA, OECD TG 442C) builds upon the original DPRA by assessing multiple substance concentrations and time points, providing quantitative reaction data. This allows for a more nuanced understanding of the reaction kinetics involved.

The application of the DPRA extends to various industries, particularly cosmetics, where skin sensitisation testing is paramount. The DPRA is used for Skin Sensitisation Testing and measures the reaction of a chemical with synthetic peptides to predict its sensitization potential. This non-animal approach is a major advance in characterization of sensitizing elements. For instance, studies have reported the successful application of the DPRA to a series of platinum compounds, including hexachloroplatinate and tetrachloroplatinate salts, highlighting its versatility.

In practice, the DPRA typically involves incubating a test chemical with a cysteine or lysine peptide for a specified period. Subsequently, the unreacted peptide is quantified, often using High-Performance Liquid Chromatography (HPLC). The DPRA then uses HPLC to measure the depletion of synthetic peptides exposed to test chemicals, thereby predicting a chemical's sensitization potential. A significant depletion of the peptide indicates a higher likelihood of skin sensitization. The assay is also technically applicable to test multi-constituent substances and mixtures of known composition, although experimental data in this area is still evolving.

The GLP Direct Peptide Reactivity Assay (DPRA) ensures that the testing is conducted under Good Laboratory Practice standards, providing reliable and reproducible results for regulatory submissions. The DPRA thus recapitulates the first key event within the skin sensitization adverse outcome pathway, offering a scientifically sound and ethically superior alternative to traditional animal testing methods for assessing skin sensitization. The DPRA is a valuable tool for toxicologists and product developers aiming to ensure the safety of chemicals and consumer products.